
==== Front
Clin Hypertens
Clin Hypertens
Clinical Hypertension
2056-5909
BioMed Central London

279
10.1186/s40885-024-00279-4
Review
The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension
Lee Hae Young 1
Ko Seung-Hyun 2
Park Sungjoon 1
Kim Kyuho 2
Kim Song-Yi 3
Cho In-Jeong 4
Cho Eun Joo 5
Kim Hyeon Chang 6
Park Jae-Hyeong 7
Ryu Sung Kee 8
Moon Min Kyong 9
http://orcid.org/0000-0001-5017-5421
Ihm Sang-Hyun limsh@cathoilc.ac.kr

10
the Korean Society of Hypertension
1 grid.31501.36 0000 0004 0470 5905 Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea
2 grid.411947.e 0000 0004 0470 4224 Department of Internal Medicine, Division of Endocrinology and Metabolism, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
3 https://ror.org/05p64mb74 grid.411842.a 0000 0004 0630 075X Department of Internal Medicine, Division of Cardiology, Jeju National University Hospital, Jeju, Republic of Korea
4 https://ror.org/053fp5c05 grid.255649.9 0000 0001 2171 7754 Department of Internal Medicine, Division of Cardiology, Ewha Womans University Seoul Hospital, Ewha Womans University College of Medicine, Seoul, Republic of Korea
5 grid.488414.5 0000 0004 0621 6849 Department of Internal Medicine, Division of Cardiology, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
6 https://ror.org/01wjejq96 grid.15444.30 0000 0004 0470 5454 Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
7 grid.254230.2 0000 0001 0722 6377 Department of Cardiology in Internal Medicine, Chungnam National University, Chungnam National University Hospital, Daejeon, Republic of Korea
8 https://ror.org/053fp5c05 grid.255649.9 0000 0001 2171 7754 Wellness Healthcare Center, Ewha Womans University Seoul Hospital, Seoul, Republic of Korea
9 grid.31501.36 0000 0004 0470 5905 Department of Internal Medicine, Division of Endocrinology & Metabolism, Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Republic of Korea
10 grid.411947.e 0000 0004 0470 4224 Department of Internal Medicine, Division of Cardiology, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
1 9 2024
1 9 2024
2024
30 245 1 2024
16 6 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Obesity is the one of the most important components of metabolic syndrome. Because obesity related hypertension accounts for two thirds of essential hypertension, managing obesity and metabolic syndrome is a crucial task in the management of hypertension. However, the current non-pharmacological therapies have limitations for achieving or maintaining ideal body weight. Recently, glucagon-like peptide-1 receptor agonists (GLP1-RAs) have demonstrated excellent weight control effects, accompanied by corresponding reductions in blood pressure. GLP1-RAs have shown cardiovascular and renal protective effects in cardiovascular outcome trials both in primary and secondary prevention. In this document, the Korean Society of Hypertension intends to remark the current clinical results of GLP1-RAs and recommend the government and health-policy makers to define obesity as a disease and to establish forward-looking policies for GLP1-RA treatment for obesity treatment, including active reimbursement policies.

Keywords

Metabolic syndrome, obesity, hypertension, glucagon
Like peptide
1, glucagon
Like peptide
1 receptor agonist
issue-copyright-statement© The Korean Society of Hypertension 2024
==== Body
pmcBackground

Metabolic syndrome (MetS) is a combination of metabolic dysfunctions mainly characterized by central obesity and insulin resistance accompanying abnormal adipose deposition and function, and the risk factors include dyslipidemia, impaired glucose tolerance, and hypertension [1]. Presence of MetS is associated with the risk of developing the cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) [2, 3]. Obesity is one of the most important components of MetS. Obesity can cause hypertension through a variety of factors and mechanisms and obesity related hypertension accounts for 65 to 75% of essential hypertension [4–6]. Conversely, the prevalence of MetS in the hypertensive population reaches almost 60% [7]. Therefore, obesity control is the essential part not only in hypertension control but also in CVD prevention [8, 9]. However, the increase in the obese population is becoming a major obstacle in the management of hypertension from a public health perspective [10]. Overweight and obesity affect more than 50% of total population worldwide [11]. Intensive lifestyle modifications, such as diet modification, regular exercise, and alcohol moderation, have been emphasized as a treatment for obesity, but their effectiveness are limited [4, 12, 13]. In addition, there are some drugs and metabolic surgeries along with lifestyle modification to treat obesity, but they also showed limited efficacy [4, 12, 13]. However, glucagon-like peptide 1 receptor agonists (GLP1-RAs), which were recently developed as a T2DM treatment drug, has been confirmed to have a strong weight control effect as well as a CVD prevention effect [14].

The Korean Society of Hypertension (KSH) defines ‘obesity’ as a disease and strives to improve hypertension management and CVD prevention through active control, including pharmacologic therapies and metabolic surgeries along with intensive lifestyle modification. Therefore, this paper reviews the expert opinions from the KSH on the effects, side effects, and considerations of GLP1-RA in hypertensive patients with obesity. In addition, the aim of this paper is to express the views of KSH and hope that these efforts can be used as important resource for the establishment of national health policies.

Prevalence of obesity / MetS among hypertensive patients

In recent decades, a global surge in obesity has become a significant concern, accompanied by the rising prevalence of MetS [15]. This issue is compounded by its intricate connection with hypertension, further emphasizing its need for urgent action [5]. Particular note is the pivotal role of central obesity in triggering hypertension and the heightened risk of MetS among the obese population, thereby amplifying the risks of hypertension [16]. Obesity rates vary worldwide, with Western higher-income countries showing signs of stabilization, while regions like Asia, Africa, the Middle East, and Central/South America experience a notable increase in obesity, particularly among children and adolescents, indicating a potential escalation in obesity-related health problems in the future [17, 18]. Obesity epidemic and the aging population has contributed to a rapid increase in hypertension prevalence, as highlighted by the Non-Communicable Disease Risk Factor Collaboration (NCD-RisC) study, which revealed a doubling in the global count of people with hypertension, from 648 million in 1990 to 1.278 billion in 2019 [19]. Despite these alarming statistics, the treatment and control of hypertension have shown improvement only in limited regions [20].

While the Korean population exhibits a lower prevalence of obesity compared to Western populations, it has a relatively higher prevalence of MetS despite the lower obesity rates [21]. Recent trends in Korea indicate a general increase in the prevalence of both obesity and MetS [21, 22], with a notable surge in obesity observed during the COVID-19 pandemic [23]. This increase is particularly pronounced among hypertensive patients. Analysis of the Korean National Health and Nutrition Examination Survey (KNHANES) data reveals that among adults aged 30 and above, the prevalence of obesity (defined as body mass index (BMI) ≥ 25 kg/m2) increased from 42% in 1998 to 52% in 2019–2021 among those with hypertension, while it increased from 24 to 31% among those without hypertension during the same period. Notably, the prevalence of severe obesity (BMI ≥ 30 kg/m2) increased from 4.3% to 10.4% among hypertensive individuals and from 1.7% to 4.3% among those without hypertension during the same period. The prevalence of MetS in adults aged ≥ 30 years with hypertension is strikingly high at 63%, compared to 20% among those without hypertension. This indicates that approximately two-thirds of hypertensive individuals have MetS (Fig. 1). These findings underscore the need for comprehensive management, addressing not only blood pressure (BP) control but also obesity and obesity-related metabolic complications among the majority of hypertensive patients [24]. Furthermore, it suggests that a significant portion of individuals requiring GLP1-RA treatment are hypertensive patients.Fig.1 Prevalence of obesity and metabolic syndrome by the presence of hypertension among Korean adults aged 30 years or older [Data Source: KNHANES 1998–2021]. BMI, body mass index

Current treatment strategy for obesity

Lifestyle modification including reducing energy intake, physical activity and behavioral therapy are the basic step of obesity treatment. A low-calorie diet that reduces energy intake by 500–1,000 kcal per day can make weight loss without negative health effect [25]. A low-carbohydrate diet (defined as daily carbohydrate intake of more than 130 g and less than 45% of total energy) led to greater initial weight loss than traditionally recommended low-fat diets and was associated with a greater improvement in CVD risk factors [26, 27]. And a systematic review and network meta-analysis that compared 14 dietary macronutrient patterns showed that most macronutrient diets resulted in modest weight loss over 6 months, but weight reduction and improvements in cardio-metabolic factors diminished after 12 months [28]. Adequate protein intake is extremely important in calorie restriction for preventing muscle mass loss regardless of diet [29].

Exercise is very important for improving lifestyle habits for weight loss. A systematic review and network meta-analysis showed that exercise led to a significant reduction of weight, fat and visceral fat. The effect of aerobic and high-intensity interval training with same energy expenditure was equal. Resistance training reduced lean mass loss during weight loss [30]. Clinical practice guideline for obesity by Korean Society for the Study of Obesity (KSSO) recommends aerobic exercise for at least 150 min per week, 3 to 5 times a week, and resistance exercise using large muscle groups 2 to 3 times per week for weight loss. Furthermore, increasing aerobic exercise to 250 to 300 min per week is suggested for more meaningful weight loss. Behavioral therapy to improve lifestyle such as reducing food intake and increasing physical activity is also recommended for weight loss and maintenance. Abstinence from alcohol and smoking also is recommended if weight loss of 2.5% is not achieved within 1 month of obesity therapy [31].

KSSO recommends that pharmacotherapy should be considered when intensive lifestyle modifications fail to achieve a weight reduction in obese patients with a BMI ≥ 25 kg/m2 and that the pharmacotherapy be changed or discontinued if weight loss is not greater than 5% within 3 months of pharmacotherapy [32]. Currently four types of obesity treatments have been approved for long-term administration in Korea: orlistat, naltrexone-bupropion, liraglutide, and phentermine-topiramate [33]. In patients with hypertension, orlistat, phentermine/topiramate ER, and liraglutide can be used and heart rate should be monitored in patients receiving phentermine/topiramate ER, and liraglutide. In case of patients with established atherosclerotic CVD, orlistat and liraglutide are recommended [34].

Indications of bariatric/metabolic surgery in Korean adults are i) with a BMI of 35 kg/m2 or more, or ii) a BMI of 30 kg/m2 or more with obesity-related comorbidities, who have failed to lose weight with non-surgical treatment and iii) with T2DM with a BMI of 27.5 kg/m2 or more and a blood glucose level that is not properly controlled with non-surgical treatment. Before performing bariatric/metabolic surgery, it is necessary for comprehensive evaluation about the patient's physical condition as well as psychosocial history and appropriate evaluation of nutritional status is required.[31].

Action mechanism and pharmacologic profile of GLP1-RAs

The connection between the pancreas, the gut, and incretin hormones was first described in the early part of the twentieth century [35]. The first incretin to be extracted from gut mucosa was gastric inhibitory polypeptide [36]. Glucagon-like peptide-1 (GLP1), a proglucagon cleavage product made by intestinal L cells, was identified in the early 1980s [37].

The promise of GLP1 as a therapeutic target in T2DM was appreciated when it was demonstrated that it contributes up to 70% of insulin production in response to nutrition intake [38]. Although natural GLP1 at pharmaceutical levels could restore the insulin secretory response in patients with T2DM, the utilization of this peptide for therapeutic purposes has been constrained by its short half-life [39]. To overcome the short half-life of endogenous GLP1 and to achieve therapeutic advantages, two approaches are being investigated; dipeptidyl peptidase-4 (DPP4) inhibitors, which prevent the breakdown of native GLP1, and the synthesis of GLP1 analogs with prolonged action [40]. Several strategies have been used to extend the biological effect of GLP1-RAs [41]. They include amino acid changes or variants to confer resistance to cleavage by DPP4 (exenatide and lixisenatide), dilution with chemical adjuncts such as zinc to delay absorption from subcutaneous tissue (taspoglutide), covalent conjugation with large molecules such as albumin or IgG to retard renal elimination (albiglutide, dulaglutide, and semaglutide), the attachment of fatty acid side chains to confer noncovalent albumin binding (liraglutide), and coupling to biodegradable polymer microspheres to confer protracted release from the subcutaneous tissue (exenatide extended-release) [41]. Presently, taspoglutide and albiglutide have been discontinued by the developer. Taspoglutide was discontinued due to instances of serious hypersensitivity reactions and gastrointestinal side effects. Albiglutide was discontinued due to limited prescribing of the drug, not due to any safety concerns in 2018. Overcoming the limitations of injectable drugs, the oral formulation of semaglutide is now licensed for use. Oral semaglutide is combined with sodium N-[8-(2-hydroxybenzoyl) amino]- caprylate (SNAC), which allows entry of semaglutide in the circulation with a bioavailability of around 1% by functioning as an absorption enhancer [42].

One of the primary actions of GLP1-RAs is to enhance insulin secretion from the pancreatic β-cells in a glucose-dependent manner [43, 44]. Unlike other insulin secretagogues that may stimulate insulin release regardless of blood glucose levels, GLP1-RAs only enhance insulin secretion when blood glucose levels are elevated. This reduces the risk of hypoglycemia, a common side effect associated with some diabetes treatments. By increasing insulin levels when needed, GLP1-RAs help lower blood glucose levels effectively. GLP1-RAs also suppress the secretion of glucagon, a hormone that increases blood glucose levels by promoting glucose production in the liver. By inhibiting glucagon release, GLP1-RAs reduce hepatic glucose output, further contributing to the reduction in blood glucose levels. This suppression occurs in a glucose-dependent manner as well, ensuring that the risk of hypoglycemia is minimized. Another significant effect of GLP1-RAs is the slowing of gastric emptying. This means that after eating, the stomach takes longer to empty its contents into the small intestine. This delay helps moderate the rise in blood glucose levels postprandially (after meals) by slowing the rate at which glucose is absorbed into the bloodstream. Moreover, this effect contributes to a feeling of fullness (satiety), which can help reduce food intake and support weight loss efforts in patients with type 2 diabetes. Some actions of GLP1-RAs, most notably the inhibition of gastric emptying [41]. GLP1-RAs have been shown to have a central effect on appetite regulation, acting on the brain to increase feelings of fullness and reduce hunger. This can lead to a decrease in calorie intake and contribute to weight loss, an important aspect of managing type 2 diabetes, as obesity is a major risk factor for the development and progression of the disease.

GLP1-RAs are primarily eliminated by the kidney. Dosing adjustments of GLP1-RAs are unnecessary due to hepatic or mild renal impairment. However, patients with moderate renal impairment should avoid weekly exenatide, and dose escalations should be carefully evaluated in patients using twice-daily exenatide. Similarly, lixisenatide usage needs to be monitored carefully in the patient population with renal impairment [45]. Dulaglutide, liraglutide, and semaglutide are approved for use down to the estimated glomerular filtration rate (eGFR) of 15 mL/min/1.73 m2. Table 1 is a summary of currently available GLP1-RAs, their basic characteristics, and indications according to renal impairment. Table 1 Characteristics of GLP1-RA

Drug	Structural class	Half-life	Administration	Renal function in eGFRa	
Short-acting	
 Exenatide	Exendin-4 derivative	 ~ 2.4 h	Subcu. twice daily	Avoid if eGFR < 30	
 Lixisenatide	Exendin-4 derivative	3–4 h	Subcu. once daily	Avoid if eGFR < 30, caution if eGFR 30–50	
Long-acting	
 Dulaglutide	Modified human GLP1	 ~ 90 h	Subcu. once weekly	Can use down to eGFR 15	
 Exenatide extended-release	Exendin-4 derivative		Subcu. once weekly	Avoid if eGFR < 30	
 Liraglutide	Modified human GLP1	11 ~ 13 h	Subcu. once daily	Can use down to eGFR 15	
 Semaglutide	Modified human GLP1	 ~ 7 days	Subcu. once weekly, oral once daily	Can use down to eGFR 15	
aeGFR in mL/min/1.73 m2

eGFR estimated glomerular filtration rate, GLP1-RA glucagon-like peptide-1 receptor agonists, subcu., subcutaneous

Body weight reducing effects with GLP1-RAs

GLP1 primarily modulates energy balance by promoting insulin secretion and additionally, it influences feeding behavior by impacting various neural circuits associated with appetite [46, 47]. GLP1 and GLP1-RAs decrease appetite and food intake by enhancing satiety and abdominal fullness with both intracerebroventricular and peripheral administration [48]. Extended treatment of GLP1-RAs at doses slightly above the standard T2DM treatment dose results in weight loss. While the reduction in HbA1c levels plateaus at relatively lower doses, higher doses may remain more effective for achieving weight loss [49, 50].

The observation that certain GLP1-RA, like albiglutide, exhibit relatively modest impact on body weight, while others, such as semaglutide, demonstrate more substantial effects despite similar glucose-lowering efficacy, has prompted interest in understanding the underlying mechanism of action. Recent data about the effects of semaglutide (and liraglutide) on obesity induced by diet in rodents suggest that the impact of systemically administered GLP1-RA on appetite, satiety, calorie intake, and body weight involves the arcuate nucleus in the hypothalamus, the area postrema, and the nucleus tractus solitarius.[51, 52] Interestingly, GLP1-RA can impact food choices by promoting the selection of healthier, less energy-dense foods in human studies [53, 54].

Prevention of new onset DM with GLP1-RAs

In adults with overweight or obesity at high risk of T2DM, care strategy should focus on weight loss to minimize the progression of hyperglycemia and associated comorbidities [55]. There are strong and consistent evidences that obesity management through intensive lifestyle modification can delay the progression from prediabetes to T2DM [56, 57]. A loss of 5–10% of body weight leads to improved lipid profile, BP, glycemic control status, and reduced incidence of T2DM, with greater benefits achieved with sustained weight loss of > 10% [58]. Based on several clinical trials, the US Food and Drug Administration (FDA) has approved two subcutaneous GLP1-RAs, liraglutide (3 mg once daily) and semaglutide (2.4 mg once weekly), as weight loss medications for long-term use in individuals with BMI ≥ 30 kg/m2 or BMI ≥ 27 kg/m2 with at least one weight-associated comorbidity, regardless of T2DM status [59]. These GLP1-RAs have been shown significant weight loss benefits. Liraglutide achieves a mean weight loss of 4–7 kg, and ≥ 50% of treated subjects achieve ≥ 5% weight loss. Semaglutide has a greater impact with a mean weight loss of 9–16 kg, and ≥ 50% of treated subjects achieve ≥ 10–15% weight loss. In the SCALE (Satiety and Clinical Adiposity e Liraglutide Evidence) obesity and prediabetes trial (n = 3,731), the mean weight loss after 56 weeks of liraglutide treatment (3.0 mg once daily) was 8.4 kg vs. 2.8 kg and a third of participants loss > 10% of their overall weight [60]. Among them, 2,254 prediabetic subjects were evaluated after a 3-year-long treatment. At the end of follow-up, conversion rate to T2DM was significantly lower in liraglutide group (6% vs 2%, placebo vs. liraglutide group, respectively), and the time to onset of T2DM over the study period was 2.7 times longer with liraglutide [61]. In the STEP (Semaglutide Treatment Effect in People with Obesity) 1 trial, semaglutide treatment (2.4 mg once weekly) for 68 weeks (n = 1,961) showed that reversion of prediabetes occurred in 84.1% of patients compared to 47.8% of controls [62].

A systematic review and meta‐analysis including eight eligible studies evaluated the beneficial effect of GLP‐1RA on prediabetes with overweight/obesity [63]. In this study, more individuals in GLP1-RAs group regressed from prediabetes to normoglycemia than subjects in the placebo group (OR = 4.56, 95% CI 3.58–5.80); fewer individuals in GLP1-RAs group were diagnosed with T2DM than those in the placebo group (OR = 0.31, 95% CI 0.12–0.81). Results of this study revealed that GLP1-RA treatment in prediabetes significantly lowered weight, fasting glucose, waist circumference, and systolic BP. In the meta-analysis including a total of 31 randomized controlled trials (n = 22,948), the mean differences (95% CI) of the pooled GLP1-RA-induced change in the HbA1c level was -0.78% (-0.97—-0.60%) in the random-effects model and -0.45% (-0.47—-0.44%) in the fixed-effect model. The pooled body weight reduction was -4.05 kg (-5.02—-3.09 kg) in the random-effects model and -2.04 kg (-2.16—-1.92 kg) in the fixed-effect model [64].

In summary, GLP1-RAs could be a promising regimen for prediabetes with overweight/obesity, particularly in terms of delaying the progression from pre-diabetes to T2DM. The effect of GLP‐1RA on the prediabetes with normal weight or the length of the treatment period needs to be refined further.

BP lowering effects with GLP1-RAs

Hypertension and diabetes often coexist, affecting approximately 60% of people aged 30 years or older with diabetes in Korea. However, among them, only half of the people achieved the target goal for BP [65]. Moreover, the combination of these two conditions increases the risk of CVD, making BP-lowering crucial for the reduction of CVD in hypertensive patients with diabetes. GLP1-RAs consistently lower BP in clinical and experimental studies.

Asmar et al. reported that acute intravenous administration of GLP-1 leads to significantly increased systolic BP and heart rate [66]. Whereas, chronic administration of GLP1-RAs has consistently reduced BP in several cardiovascular outcome trials (Table 2) [67–75]. In the ELIXA study (The Evaluation of Lixisenatide in Acute Coronary), the addition of lixisenatide to usual care did not significantly reduce the major cardiovascular outcomes, however, it did show a significant decrease in systolic BP (mean -0.8 mm Hg) and an increased heart rate (+ 0.4 beats per minute) compared to the placebo group [67]. In the LEADER study (the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome), the first study of positive cardiovascular outcomes of GLP1-RA, systolic BP was lower (-1.2 mm Hg), but diastolic BP was higher (+ 0.6 mm Hg), and heart rate (+ 3.0 beats per minute) was increased in the liraglutide group compared to the placebo group [69]. Moreover, the SUSTAIN-6 trial (Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes) showed dose-dependent systolic BP decrease and an increase in heart rate in semaglutide group [68]. These findings were similar to the PIONEER 6 study (Peptide Innovation for Early Diabetes Treatment) with oral semaglutide [74]. The BP-lowering effect of GLP1-RAs was similar between the short-acting and long-acting formulations. The result Harmony outcomes (Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease) with albiglutide, a long-acting formulation of GLP1-RA, slightly reduced the mean systolic BP in the albiglutide group compared with the placebo group, and BP difference was similar between 8 and 16 months (-0.65 and -0.67 mm Hg at 8 months and 16 months) [71]. The REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) study with a long-acting dulaglutide showed similar findings with systolic BP decrease and heart rate increase [72]. In the meta-analysis, compared with placebo, and other antidiabetic treatments including insulin, and sulfonylureas, GLP1-RAs decreased systolic BP (range from -1.84 mm Hg to 4.60 mm Hg) compared with the placebo group, but diastolic BP was only significantly reduced in exenatide use (-1.08 mm Hg) [76]. Table 2 Change difference of body weight and blood pressure (BP) in major cardiovascular outcomes trials of GLP1-RAs

Study acronym	GLP1-RA	Follow up duration	Population	Baseline
BMI	Body weight change (kg)	Systolic BP change	
ELIXA

[67]

	Lixisenatide	25 months	T2DM with CVD	30.2	-0.7 kg	-0.8 mmHg	
LEADER

[69]

	Liraglutide	3.8 years	T2DM with high CVD risk	32.5	-2.3 kg	-1.2 mmHg	
SUSTAIN-6

[68]

	Semaglutide	2 years	T2DM	33	–2.9 kg (0.5 mg)—–4.3 kg (1.0 mg)	-1.3 mmHg (0.5 mg)

-2.6 mmHg (1.0 mg)

	
EXSCEL

[70]

	Exenatide	3.2 years	T2 DM with / without CVD	31.8	-1.27 kg	-1.57 mmHg	
Harmony Outcomes

[71]

	Albiglutide	1.6 years	T2DM with CVD	32.3	–0.83 kg	–0.67 mmHg	
REWIND

[72]

	Dulaglutide	5.4 years	T2 DM with ≥ 50 years with a previous CVD or ≥ 60 years ≥ 2 CVD risks	32.3	-1.46 kg	-1.70 mmHg	
PIONEER6

[73]

	Semaglutide Oral	15.9 months	 ≥ 50 years with CVD or ≥ 60 years with CVD risk factors	32.3	–3.4 kg	-2.6 mmHg	
STEP-HFpEF

[74]

	Semaglutide	1 year	HFpEF with BMI ≥ 30 kg/m2	37	-14 kg	-2.9 mmHg	
SELECT

[75]

	Semaglutide	34.2 months	Non-DM ≥ 45 years with CVD and BMI > 27 g/m2	33.4	-9.1 kg	-3.82 mmHg	
All trials were multicenter, double-blind, randomized placebo-controlled trial. T2DM, type 2 diabetes mellitus, CVD cardiovascular disease

DMI body mass index, BP blood pressure, CVD cardiovascular disease, DM diabetes mellitus, HFpEF heart failure with preserved ejection fraction, GLP1-RA glucagon-like peptide-1 receptor agonists

There are several mechanisms postulated regarding BP reduction with GLP1-RAs [77, 78]. Weight reduction was positively associated with systolic and diastolic BP reduction in a meta-analysis [79]. However, this BP-lowering effect occurred in the early period, within 2–4 weeks of drug administration before significant weight loss, suggesting that BP reduction might be independently associated with weight loss [77, 80, 81]. These effects became plateau within 8–12 weeks and were maintained up to 2 years [77]. GLP1 receptor has been found to be expressed in endothelial cells and vascular smooth muscle cells in several organs including the heart, brain, kidney, and blood vessels [77, 78]. In animal studies, GLP1-RA treatment increased endothelial nitric oxide synthase [82], led to direct vascular relaxation [83], decreased vascular remodeling,[84] and reduced intercellular adhesion molecule expression,[82] mitigating endothelial dysfunction, vascular inflammation, and arterial stiffness [78]. GLP1-RA treatment enhanced the secretion of atrial natriuretic peptide on atrial cardiomyocytes in a mouse model, promoting natriuresis and smooth muscle relaxation [85]. Also, the administration of GLP1 or GLP1-RAs induced dose-dependent diuresis and natriuresis, linked to increased glomerular filtration rate in rodents [86] and obese men.[87] GLP1-RAs suppress sympathetic activation on the central (hypothalamus and brainstem) [88] and peripheral nervous system (carotid body) in animal studies [89]. Consequently, GLP1-RAs have favorable effects on BP-lowering by mitigating endothelial dysfunction and vascular contraction, preventing vascular remodeling, promoting diuresis and natriuresis, and suppressing sympathetic activation.

Ancillary effect on vascular function with GLP1-RAs

GLP1-RAs improve endothelial function in several ways in addition to their glucose-lowering effects. Increased nitric oxide (NO) production is the first mechanism. In human vascular endothelial cells, liraglutide increased NO production by stimulating phosphorylation of endothelial nitric oxide synthase, the enzyme that produces NO, in a 5' AMP-activated protein kinase-dependent manner [90]. The second mechanism is reducing oxidative stress. GLP1-RAs reduced reactive oxygen species and the expression of vascular cell adhesion molecule-1 mRNA in endothelial cells after exposure to advanced glycation end products [91]. In addition, GLP1-RAs reduce oxidative stress by increasing the production of antioxidants such as glutathione and NO. The third mechanism is the improvement of mitochondrial function. GLP1 RAs improve mitochondrial function by increasing mitochondrial biogenesis and reducing mitochondrial apoptosis [92]. It recovers mitochondrial membrane potential, oxygen consumption and myeloperoxidase levels. The final mechanism is the reduction of inflammation. GLP1-RAs have anti-inflammatory effects through a variety of mechanisms, including the reduction of pro-inflammatory cytokine production and the increase of anti-inflammatory cytokine production. GLP1-RAs inhibit the formation of macrophage foam cells [93]. Treatment with liraglutide increased NO production and reduced tumor necrosis factor α -induced nuclear factor kappa B activation [90]. Several GLP1-RAs have been shown to be effective in the reduction of systemic inflammation, as measured by C-reactive protein levels [94].

Beyond their effects on glucose metabolism and weight, GLP1-RAs also influence lipid metabolism [95, 96]. These agents have been shown to modulate lipid synthesis and secretion, contributing to improved lipid profiles in patients with T2DM. The mechanisms behind these effects are multifaceted. GLP1-RAs can reduce hepatic lipogenesis, the process by which the liver synthesizes fatty acids and triglycerides. Additionally, they may enhance the clearance of lipids from the bloodstream, through mechanisms that include increased lipoprotein lipase activity, leading to a reduction in circulating triglycerides. Furthermore, GLP1-RAs have been observed to impact the secretion of very low-density lipoprotein (VLDL) particles by the liver, which are a major carrier of triglycerides.

GLP1-RAs have beneficial effects on the vasculature in two ways, directly and indirectly. GLP1-RAs can directly relax vascular smooth muscle cells, thereby reducing vascular stiffness. Liraglutide, independent of its glucose-lowering effect, may inhibit angiotensin II-induced vascular smooth muscle cell proliferation by activating AMP-activated protein kinase signaling and inducing cell cycle arrest, thereby delaying the progression of atherosclerosis [97]. Also, GLP1-RAs can produce NO that relaxes blood vessels and improves blood flow and have favorable effects on endothelial function indicators, such as the reactive hyperemia index and flow-mediated dilatation, these can attenuate vascular stiffness [98, 99]. Indirectly, GLP1-RA induced positive vascular effects may be associated with improvements in glucose and lipid metabolism, weight reduction, and BP lowering effects. GLP1-RAs can improve metabolic profiles and reduce vascular adipose tissue-derived inflammation, subsequently [100]. Additionally, they have a favorable effect on BP, improving vascular stiffness.

The potential impact of GLP1-RAs on CV risk factors extends to thrombosis and platelet aggregation [101]. Emerging evidence suggests that GLP1-RAs may exert protective effects against thrombosis by influencing the function of platelets and the coagulation cascade. These agents have been shown to reduce platelet activation and aggregation, mechanisms that are crucial in the formation of thrombi and the development of cardiovascular events such as myocardial infarction and stroke. The anti-thrombotic effects of GLP1-RAs are thought to be mediated through both direct and indirect pathways. Directly, GLP1-RAs may influence platelet function through GLP-1 receptors expressed on platelets themselves. Indirectly, the reduction in systemic inflammation, improvement in endothelial function, and amelioration of atherosclerotic changes associated with GLP-1RA therapy may contribute to their anti-thrombotic effects.

Target organ protection by GLP1-RAs

Through several clinical studies, the cardiovascular protective effects of GLP1-RAs have been demonstrated. In the LEADER study, SUSTAIN-6 study, Harmony Outcomes study, and REWIND study, liraglutide, semaglutide, albiglutide, and dulaglutide showed a significant reduction in major adverse cardiac events (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke) compared to the placebo group, respectively [68, 69, 71, 72]. On the other hand, in the ELIXA study, EXSCEL study, and PIONEER 6 study, exenatide, extended-release exenatide, and oral semaglutide groups demonstrated non-inferiority regarding cardiovascular safety compared to the placebo, respectively[67, 70, 73]. When meta-analyzing these seven randomized controlled trials, GLP1-RAs were found to reduce major CVD events by 12% (hazard ratio [HR], 0.88; 95% CI, 0.82–0.94), CVD mortality by 12% (HR, 0.88; 95% CI, 0.81–0.96), and stroke risk by 16% (HR, 0.84; 95% CI, 0.76–0.93) [102]. Very recently, semaglutide reduced the risk of major cardiovascular events by 20% compared with placebo in non-diabetic patients who are overweight or obese and with pre-existing CVD [75].

GLP1-RAs have also shown potential benefits in heart failure. Meta-analysis revealed promising trends regarding heart failure outcomes in terms of reduced rate of heart failure-related events [103]. The effect of Semaglutide 2.4 mg Once Weekly on Function and Symptoms in Subjects with Obesity-related Heart Failure with Preserved Ejection Fraction (STEP-HFpEF) trial reported that semaglutide led to greater weight loss, heart failure related symptom improvement and to significant difference in 6-min walk distance when compared to placebo in patients with preserved left ventricular ejection fraction ≥ 45% and obesity (BMI ≥ 30 kg/m2) [74].

GLP1-RAs, particularly longer-acting formulations, reduced stroke events in T2DM [104]. The effects of GLP1-RAs on stroke subtypes gave discordant results in placebo-controlled outcome trials. An exploratory analysis in the REWIND trial indicated that dulaglutide might reduce the incidence but not severity of ischemic stroke (3.2% on dulaglutide versus 4.1% on placebo, corresponding to a 24% risk reduction with dulaglutide versus placebo) [105]. However, no effects were seen on hemorrhagic stroke. In contrast, a post hoc analysis of SUSTAIN 6 and PIONEER 6 showed that semaglutide reduced the risk of any stroke by 32% compared with placebo, with no difference between stroke subtypes [106].

The renal effects of GLP1-RAs have garnered significant attention in recent years, reflecting a broader understanding of their benefits beyond glycemic control in patients with T2DM [107, 108]. The renal benefits of GLP1-RAs are mediated through several mechanisms, which include improving hemodynamics, reducing inflammation, and attenuating oxidative stress in the kidneys. These agents have been shown to reduce glomerular hyperfiltration, a condition commonly seen in the early stages of diabetic nephropathy, by improving the tubuloglomerular feedback. This results in a reduction of intraglomerular pressure, thereby slowing the progression of kidney damage. Additionally, GLP1-RAs can decrease albuminuria, which is an early marker of diabetic nephropathy and a predictor of renal and cardiovascular outcomes. The reduction in albuminuria with GLP1-RAs is believed to be independent of their glucose-lowering effects and may result from direct anti-inflammatory and antifibrotic effects on the kidneys. These agents are also thought to improve renal outcomes by reducing systemic and renal inflammation, as evidenced by decreases in markers of inflammation such as C-reactive protein and interleukin-6. Several large cardiovascular outcome trials (CVOTs) have highlighted the renal benefits of GLP1-RAs. The LEADER trial, which investigated liraglutide, demonstrated a significant reduction in the risk of new-onset persistent macroalbuminuria, although there were no significant differences in the rates of doubling of serum creatinine, the need for renal replacement therapy, or death due to renal disease. Similarly, the SUSTAIN-6 trial with semaglutide showed a reduction in new or worsening nephropathy. These findings are complemented by real-world studies and meta-analyses that further support the renal protective effects of GLP1-RAs. In a meta-analysis, GLP1-RAs were shown to reduce the risk of renal composite outcomes (occurrence of sustained macroalbuminuria, doubling of serum creatinine, glomerular filtration rate decrease of 30% or 40%, need for renal replacement therapy, or death due to renal disease) by 17% [102]. And GLP1-RAs are reported to have positive effects on non-alcoholic fatty liver disease (NAFLD) [109]. In patients with NAFLD, liraglutide reduced liver and visceral fat, improving liver histology and function [110].

Adverse effects of GLP1-RAs

The most common side effects of GLP1-RAs are gastrointestinal symptoms, including nausea, vomiting, and diarrhea, which are the main reasons for drug discontinuation [111]. The incidence of adverse reactions in the digestive system varies depending on the type and dose of the GLP1-RAs and the type of concomitant hypoglycemic agents. Nausea mostly disappears after a few weeks of administration and can be minimized by starting with a low dose and gradually increasing the dose. While nausea and vomiting are more common with short-acting agents, side effects such as itching or nodules at the injection site appear more frequently with long-acting agents and usually disappear in 3 to 4 weeks [112]. The safety and tolerability of GLP1-RAs with respect to renal function are generally favorable. However, like any therapeutic agents, they are associated with potential side effects, including gastrointestinal symptoms, which are the most common. There is also a theoretical risk of acute kidney injury, primarily through volume depletion due to nausea or vomiting, but this risk is considered low and manageable with appropriate patient monitoring and hydration.

GLP1-RA therapy has been associated with an increased risk of gallbladder and biliary tract diseases, including cholelithiasis and cholecystitis. In a meta-analysis including 76 studies, GLP1-RA therapy significantly increased the relative risk of the composite outcome of gallbladder or biliary tract disease [113]. In particular, the risk increased with the use of GLP1-RAs for weight loss, high doses, and long-term treatment. Post-marketing surveillance reports also reported an increased risk of acute cholecystitis due to GLP1-RA treatment.[114] Animal model studies have suggested that GLP1-RAs may cause pancreatitis and exocrine dysplasia [115], however, in large randomized controlled trials, GLP1-RAs did not increase the risk of pancreatitis or pancreatic cancer. Currently, the US FDA and the European Medicines Agency have concluded that there is no direct possibility with GLP1-RAs [116].

Although the risk of hypoglycemia is very low due to its glucose-dependent mechanism of action, the risk of hypoglycemia may increase when used in combination with medications that can cause hypoglycemia [117]. Antibodies to GLP1-RAs may develop. Generally, the titer of antibodies decreases over time and does not affect glycemic control.

In rodent animal models, GLP1-RA increases thyroid parafollicular cell (C-cell) proliferation and tumorigenesis [118]. This is because not only do rodent C-cells express more GLP1 receptors than humans, but there is also a higher incidence of thyroid C-cell carcinoma. There are no data in humans, but it should not be used in patients with a past or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 [119]. Angioedema and anaphylaxis have been rarely reported with GLP1-RAs, including semaglutide, liraglutide, dulaglutide, exenatide, and lixisenatide [120].

Position of GLP1-RAs in the clinical guidelines

GLP1-RAs have increasingly become integral to the management of T2DM and, more recently, have been recognized for their cardiovascular benefits. Their inclusion in clinical guidelines reflects their efficacy in improving glycemic control, promoting weight loss, and reducing cardiovascular risk. This discussion focuses on the role of GLP1-RAs in current clinical guidelines, particularly those related to diabetes and cardiovascular disease management.

In the management of T2DM, GLP1-RAs are recommended as part of a comprehensive treatment strategy that may include lifestyle modifications, metformin (considered the first-line treatment in most guidelines), and other glucose-lowering medications. The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), in their consensus report, highlight the use of GLP1-RAs, especially in patients with T2DM who have established atherosclerotic CVD, heart failure, or chronic kidney disease, given their proven benefit in reducing major adverse CV events (MACE) [121]. The guidelines prioritize drugs with proven cardiovascular benefits for patients with T2DM and established CVD or indicators of high risk. GLP1-RAs, along with the sodium-glucose cotransporter-2 (SGLT2) inhibitors, are preferred in such cases due to their ability to address both glycemic control and cardiovascular risk factors effectively. Emerging evidence of the cardiovascular benefits of GLP1-RAs has led to their inclusion in guidelines beyond diabetes management. For instance, the 2019 European Society of Cardiology (ESC) guidelines for the management of T2DM, pre-diabetes, and CVD developed in collaboration with the EASD recognize the role of GLP1-RAs in reducing the risk of MACE in patients with T2DM and CVD [122]. These guidelines recommend considering these agents as part of the treatment regimen for such patients, reflecting a shift towards a more CV protective approach in managing T2DM.

Economical concern of GLP1-RAs

The economic burden of obesity on healthcare systems is substantial, making effective and cost-efficient treatments essential. The aggregate medical cost of obesity in the U.S. was 260 billion USD in 2016 (1.5% of the gross domestic product), equating to 20% of all health care expenditures [123]. Globally, it is estimated that obesity-related complications will cost 1.2 trillion USD by 2025, and a 5% weight loss in obese patients can improve their health and reduce the incidence of obesity-related complications [124]. The economic consideration of using GLP1-RAs in obesity care can be examined from multiple angles. The primary economic advantage of GLP1-RAs in obesity care lies in their potential to reduce obesity-related healthcare costs. By facilitating weight loss and improving metabolic health,these medications can mitigate the need for treatments and hospitalizations relatedto obesity-related conditions. This leads to lower direct medical costs for healthcare systems.

Several studies have assessed the cost-effectiveness of using GLP1-RAs in obesity care. These studies consider several factors such as medication costs, the degree of weight loss achieved, and the potential reduction in obesity-related healthcare expenditures. The cost-effectiveness of anti-obesity medications were estimated in obese population model of 78.2% females with a mean age of 45 years and BMI of 37.1 kg/m2 for women and 36.8 kg/m2 for men [125]. Of five anti-obesity medications, tirzepatide, semaglutide, liraglutide, phentermine plus topiramate, and naltrexone plus bupropion, of which monthly medication costs were estimated as approximately 739, 1023, 1023, 151, and 230 USD, respectively, phentermine plus topiramate was considered as the most cost-effective treatment, mainly because of its low price and similar effectiveness. To achieve a cost-effectiveness ratio of 150,000 USD, the price of tirzepatide would need to be reduced more than 38% to become cost-effective need. In a cost-effectiveness analysis of four GLP-1RA (liraglutide 1.8 mg once daily, semaglutide 1.0 mg weekly, dulaglutide 1.5 mg weekly, or exenatide 10 μg twice daily) compared with no-treatment group. Their monthly medication costs were estimated as 921.9, 827.7, 813.6, and 729.6 USD, respectively. Only semaglutide provided a cost-effective strategy based on a willing-to-pay threshold of $195,000/quality-adjusted life years (QALYs) with an incremental cost-effectiveness ratios (ICER) of $135,467/QALY, owing to superior efficacy of BMI reduction.[126] In case of semaglutide, semaglutide 2.4 mg in the treatment of adult patients with obesity (ie, BMI ≥ 30 kg/m2) and adult patients who are overweight (ie, BMI 27–29.9 kg/m2) with 1 or more weight-related comorbidities was estimated to be cost-effective compared with no treatment, diet and exercise alone, and all other branded anti-obesity medications (liraglutide 3 mg, phentermine-topiramate, and naltrexone-bupropion) under a willing-to-pay threshold of 150,000 USD per QALY gained over a 30-year time horizon [127]. In this study, the cost for semaglutide 2.4 mg was estimated as 17,597.48 USD annually, and was estimated to be particularly cost-effective in the subgroup of obese patients with BMI ≥ 40 kg/m2 without T2DM. However, in less risk population of adolescents ages 15 years and older with BMI ≥ 37 kg/m2, top-dose phentermine and topiramate might be the preferred strategy with an ICER of 56,876 USD per QALY gained vs lifestyle counseling. Semaglutide was projected to yield the most QALYs, but with an unfavorable ICER of 1.1 million USD per QALY gained, which would need to be reduced more than 85% to become cost-effective.[128]. Their monthly medication costs were estimated as 191 and 1,295 USD, respectively. Even semaglutide was considered as less cost-effective compared with sleeve gastrectomy [129]. For semaglutide to be cost-effective when compared with sleeve gastrectomy, it would have to cost less than 1,879 USD (class III), 1,204 USD (class II) or 297 USD (class I) annually.

It is undeniable that GLP1-RAs for weight loss is expensive, far exceeding to cost-effective range. However, this limitation can be substantially reduced if GLP1-RAs are reimbursed by health insurance system for at least high-risk obese patients. However, the insurance coverage of anti-obesity medications is very limited. A study analyzing 136 marketplace health insurance plans showed that just 11% had some coverage for any kind of anti-obesity medications in the US [130]. An important consideration in the anti-obesity pharmacotherapy with GLP1-RA is the health equity. Even in diabetic patients who were commercially insured, Asian, Black, and Hispanic individuals had lower use of GLP1-RA, while higher household income was independently associated with higher use [131]. However, for expanding access for diabetic patients, obesity aside, in low-income and middle-income countries, GLP1-RA would require price reductions by approximately 98% (208 USD annually), to meet a common cost-effectiveness threshold of achieving incremental costs per incremental DALY averted less than three times the GDP per capita over sulfonylurea therapy alone [132].

Practical tips of GLP1-RAs in obesity care

The use of GLP1-RAs in clinical practice involves several practical considerations, including patient selection, choice of agent, and strategies for initiation and up-titration. The selection of patients for GLP1-RA therapy should be individualized, considering factors such as the patient's cardiovascular risk profile, need for weight loss, glycemic targets, and potential side effects. GLP1-RAs are particularly beneficial for patients with T2DM who have a high risk of CVD or established CVD, given the cardiovascular benefits demonstrated in several CVOTs. Also, overweight or obese patients could benefit from weight reduction.

The choice among GLP1-RAs should be based on factors such as the agent's efficacy, safety profile, dosing frequency, patient preference, and cost. Some GLP1-RAs are administered via subcutaneous injection daily, while others are available as weekly formulations, which may be more convenient for patients and improve adherence. The efficacy in terms of glycemic control and weight loss, as well as cardiovascular benefits, varies slightly among agents, so choosing an agent should also consider the individual patient's health goals and risk factors. Initiating GLP1-RA therapy involves starting at a lower dose to minimize gastrointestinal side effects, such as nausea and vomiting, which are the most common adverse effects associated with these agents. A gradual up-titration of the dose is recommended until the therapeutic dose is reached or the maximum tolerated dose is identified. This approach helps improve tolerability and patient adherence to therapy. Patient education is crucial during this phase to set realistic expectations regarding potential side effects and the importance of adherence to the titration schedule. Monitoring the patient's response to GLP1-RA therapy is essential for ensuring optimal outcomes. This includes regular assessments of glycemic control, weight, blood pressure, and potential side effects. Adjustments to the therapy may be necessary based on the patient's response and tolerability. In some cases, combining GLP1-RAs with other antidiabetic medications may be considered to achieve glycemic targets.

Gut-CV connection with GLP1-RAs

The gut-CV connection highlights the intricate interplay between the gastrointestinal system and CV health, an area of growing research interest. One significant aspect of this connection is the role of the gut microbiome, which comprises trillions of microorganisms residing in the gastrointestinal tract. These microorganisms have a profound impact on metabolic, immunological, and physiological processes, including those related to cardiovascular health. GLP1-RAs, a class of medications primarily used in the management of T2DM, have been shown to offer CV benefits, and emerging evidence suggests that their effects may be partly mediated through the gut microbiome [133]. Research suggests that the gut microbiota can influence the efficacy of GLP1-RAs in several ways. Firstly, the composition of the gut microbiota affects the metabolism and bioavailability of these drugs, potentially influencing their therapeutic effects. Secondly, GLP1-RAs have been shown to alter the composition of the gut microbiota, promoting the growth of beneficial bacterial species that have been associated with improved metabolic outcomes and reduced cardiovascular risk. Moreover, the gut microbiome influences the production of short-chain fatty acids (SCFAs) through the fermentation of dietary fibers. SCFAs have been shown to have several beneficial effects on cardiovascular health, including anti-inflammatory properties, blood pressure regulation, and improvement of lipid metabolism. GLP1-RAs may enhance the production of SCFAs by altering the gut microbiota composition, thereby contributing to their CV benefits.

Ongoing CV outcome trials of GLP1 agonists

The ongoing CVOTs of GLP1-RAs are pivotal in understanding the impact of these therapies on cardiovascular outcomes in patients with T2DM and a history of or high risk for CVD. Table 3 is a summary of the ongoing CVOTs withe GLP1-RAs. Table 3 Ongoing cardiovascular outcomes trials of GLP1-RAs

Agent	Company	Development stage	Indication	ClinicalTrials.gov ID	
GLP1/glucagon dual agonists	
 Cotadutide	AstraZeneca	Phase III	NASH	NCT05364931

(active, not recruiting)

	
 Survodutide	Boehringer Ingelheim	Phase III	Obesity	NCT06066515 (recruiting)	
 Efinopegdutide	MSD	Phase II	NASH	NCT05877547 (recruiting)	
 Mazdutide	Eli Lilly	Phase III	Obesity	NCT05607680

(active, not recruiting)

	
 DA-1726	NeuroBo Pharmaceuticals	Phase I	Obesity	NCT06252220

(not yet recruiting)

	
GIP/GLP1 dual agonists	
 Tirzepatide	Eli Lilly	Phase II	NASH	NCT04166773

(active, not recruiting)

	
 NN9709	Novo Nordisk	Discontinued	Obesity, T2D	NCT02205528 (completed)	
GIP/GLP1/glucagon tri-agonists	
 HM15211	Hanmi Pharmaceutical	Phase II	NASH	NCT04505436 (recruiting)	
 Retatrutide	Eli Lilly	Phase III	Obesity	NCT05882045 (recruiting)	
 NN9423	Novo Nordisk	Discontinued	Obesity, T2D	NCT03661879 (completed)	
GLP1R agonists	
 Efpeglenatide	Hanmi Pharmaceutical	Phase III	T2D	NCT03353350 (completed) NCT03496298 (terminated)	
Phase II	NASH	NCT04505436 (recruiting)	
 Danuglipron	Pfizer	Phase II	Obesity	NCT04707313 (completed)	
Phase II	T2D	NCT03985293 (completed)	
 Orforglipron	Eli Lilly	Phase III	T2D	NCT05872620 (recruiting)	
Obesity	NCT05869903 (recruiting)	
 Lotiglipron	Pfizer	withdrawn			

Summary and conclusion

Managing obesity and metabolic syndrome is a crucial task in the management of hypertension. However, the current non-pharmacological therapies have limitations.

GLP1-RAs demonstrate excellent weight control effects, accompanied by corresponding reductions in BP.

GLP1-RAs have shown cardiovascular and renal protective effects in cardiovascular outcome trials both in primary and secondary prevention.

The Korean Society of Hypertension defines obesity as a disease and aims to improve hypertension control rates and prevent CVDs through active management, including drug therapy. In this regard, there is a positive evaluation of the weight loss and BP control effects of GLP1-RAs.

High costs and gastrointestinal side effects impose restrictions on usage. Future research should focus on cost-effectiveness studies regarding the management of CVDs in comparison to drug prices. Additionally, it is urged that the government classifies obesity as a disease and establishes active reimbursement policies for control medications.

Abbreviations

ADA American Diabetes Association

BMI Body mass index

CVD Cardiovascular disease

eGFR Estimated glomerular filtration rate

EASD European Association for the Study of Diabetes

ESC European Society of Cardiology

FDA US Food and Drug Administration

GLP1 Glucagon-like peptide-1

GLP1-RAs Glucagon-like peptide-1 receptor agonists

KSH Korean Society of Hypertension

KSSO Korean Society for the Study of Obesity

MetS Metabolic syndrome

NAFLD Non-alcoholic fatty liver disease

NO Nitric oxide

QALYs Quality-adjusted life years

SGLT2 Sodium-glucose cotransporter-2

SNAC Sodium N-[8-(2-hydroxybenzoyl) amino]-caprylate

T2DM Type 2 diabetes mellitus

Acknowledgements

None.

Author’s contributions

SHK, and HYL conceived the project and wrote and reviewed the manuscript; SHK, SP, KK, SYK, IJC, EJC, HCK, JHP, SKR, and MKM wrote and reviewed the manuscript; SHI reviewed and revised the manuscript.

Funding

No funding.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

Jae-Hyeong Park and In-Jeong Cho serves on the editorial boards as a deputy editor in the Clinical Hypertension.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Hae Young Lee and Seung-Hyun Ko contributed equally to this work.
==== Refs
References

1. Kahn R Buse J Ferrannini E Stern M The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2005 28 9 2289 2304 10.2337/diacare.28.9.2289 16123508
Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005;28(9):2289–304.16123508 10.2337/diacare.28.9.2289
2. Wilson PWF D’Agostino RB Parise H Sullivan L Meigs JB Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus Circulation 2005 112 20 3066 72 10.1161/CIRCULATIONAHA.105.539528 16275870
Wilson PWF, D’Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus. Circulation. 2005;112(20):3066–72.16275870 10.1161/CIRCULATIONAHA.105.539528
3. Kim HC Lee H Lee HH Lee G Kim E Song M Korea hypertension fact sheet 2022: analysis of nationwide population-based data with a special focus on hypertension in the elderly Clin Hypertens 2023 29 1 22 10.1186/s40885-023-00243-8 37580841
Kim HC, Lee H, Lee HH, Lee G, Kim E, Song M, et al. Korea hypertension fact sheet 2022: analysis of nationwide population-based data with a special focus on hypertension in the elderly. Clin Hypertens. 2023;29(1):22.37580841 10.1186/s40885-023-00243-8
4. Jung MH Ihm SH Obesity-related hypertension and chronic kidney disease: from evaluation to management Kidney research and clinical practice 2023 42 4 431 444 10.23876/j.krcp.23.072 37551125
Jung MH, Ihm SH. Obesity-related hypertension and chronic kidney disease: from evaluation to management. Kidney research and clinical practice. 2023;42(4):431–44.37551125 10.23876/j.krcp.23.072
5. Hall JE do Carmo JM da Silva AA Wang Z Hall ME Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms Circulation Research 2015 116 6 11991 1006 10.1161/CIRCRESAHA.116.305697
Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circulation Research. 2015;116(6):11991–1006.10.1161/CIRCRESAHA.116.305697
6. Park S Shin J Ihm SH Kim KI Kim HL Kim HC Resistant hypertension: consensus document from the Korean society of hypertension Clin Hypertens 2023 29 1 30 10.1186/s40885-023-00255-4 37908019
Park S, Shin J, Ihm SH, Kim KI, Kim HL, Kim HC, et al. Resistant hypertension: consensus document from the Korean society of hypertension. Clin Hypertens. 2023;29(1):30.37908019 10.1186/s40885-023-00255-4
7. Lee SR Cha MJ Kang DY Oh KC Shin DH Lee HY Increased prevalence of metabolic syndrome among hypertensive population: ten years' trend of the Korean National Health and Nutrition Examination Survey Int J Cardiol 2013 166 3 633 639 10.1016/j.ijcard.2011.11.095 22192283
Lee SR, Cha MJ, Kang DY, Oh KC, Shin DH, Lee HY. Increased prevalence of metabolic syndrome among hypertensive population: ten years’ trend of the Korean National Health and Nutrition Examination Survey. Int J Cardiol. 2013;166(3):633–9.22192283 10.1016/j.ijcard.2011.11.095
8. Shin D Choi J Lee HY Suboptimal control status of young hypertensive population Clin Hypertens 2023 29 1 13 10.1186/s40885-023-00237-6 37122032
Shin D, Choi J, Lee HY. Suboptimal control status of young hypertensive population. Clin Hypertens. 2023;29(1):13.37122032 10.1186/s40885-023-00237-6
9. Kim HL Lee EM Ahn SY Kim KI Kim HC Kim JH The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension Clin Hypertens 2023 29 1 11 10.1186/s40885-023-00234-9 36788612
Kim HL, Lee EM, Ahn SY, Kim KI, Kim HC, Kim JH, et al. The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension. Clin Hypertens. 2023;29(1):11.36788612 10.1186/s40885-023-00234-9
10. Chowdhury MZI Rahman M Akter T Akhter T Ahmed A Shovon MA Hypertension prevalence and its trend in Bangladesh: evidence from a systematic review and meta-analysis Clin Hypertens 2020 26 10 10.1186/s40885-020-00143-1 32514373
Chowdhury MZI, Rahman M, Akter T, Akhter T, Ahmed A, Shovon MA, et al. Hypertension prevalence and its trend in Bangladesh: evidence from a systematic review and meta-analysis. Clin Hypertens. 2020;26:10.32514373 10.1186/s40885-020-00143-1
11. Khera A Powell-Wiley TM SELECTing Treatments for Cardiovascular Disease - Obesity in the Spotlight N Engl J Med 2023 389 24 2287 2288 10.1056/NEJMe2312646 37952130
Khera A, Powell-Wiley TM. SELECTing Treatments for Cardiovascular Disease - Obesity in the Spotlight. N Engl J Med. 2023;389(24):2287–8.37952130 10.1056/NEJMe2312646
12. Jensen MD Ryan DH Apovian CM Ard JD Comuzzie AG Donato KA 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society Circulation 2014 129 25 Suppl 2 S102 S138 24222017
Jensen MD, Ryan DH, Apovian CM, Ard JD, Comuzzie AG, Donato KA, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102–38.24222017
13. Shariq OA McKenzie TJ Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery Gland Surg 2020 9 1 80 93 10.21037/gs.2019.12.03 32206601
Shariq OA, McKenzie TJ. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 2020;9(1):80–93.32206601 10.21037/gs.2019.12.03
14. Ussher JR Drucker DJ Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action Nat Rev Cardiol 2023 20 7 463 474 10.1038/s41569-023-00849-3 36977782
Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463–74.36977782 10.1038/s41569-023-00849-3
15. NCD Risk Factor Collaboration (NCD-RisC). Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight. Elife. 2021;10:e60060.
16. Landsberg L Aronne LJ Beilin LJ Burke V Igel LI Lloyd-Jones D Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension J Clin Hypertens (Greenwich) 2013 15 1 14 33 10.1111/jch.12049 23282121
Landsberg L, Aronne LJ, Beilin LJ, Burke V, Igel LI, Lloyd-Jones D, et al. Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension. J Clin Hypertens (Greenwich). 2013;15(1):14–33.23282121 10.1111/jch.12049
17. Bluher M Obesity: global epidemiology and pathogenesis Nat Rev Endocrinol 2019 15 5 288 298 10.1038/s41574-019-0176-8 30814686
Bluher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–98.30814686 10.1038/s41574-019-0176-8
18. Collaboration NCDRF. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627–42.
19. Collaboration NCDRF. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–80.
20. Schutte AE Jafar TH Poulter NR Damasceno A Khan NA Nilsson PM Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension Cardiovasc Res 2023 119 2 381 409 10.1093/cvr/cvac130 36219457
Schutte AE, Jafar TH, Poulter NR, Damasceno A, Khan NA, Nilsson PM, et al. Addressing global disparities in blood pressure control: perspectives of the International Society of Hypertension. Cardiovasc Res. 2023;119(2):381–409.36219457 10.1093/cvr/cvac130
21. Park D, Shin M-J, Després J-P, Eckel RH, Tuomilehto J, Lim S. 20-Year Trends in Metabolic Syndrome Among Korean Adults From 2001 to 2020. JACC: Asia. 2023;3(3_Part_2):491–502.
22. Kim Y Nho SJ Woo G Kim H Park S Kim Y Trends in the prevalence and management of major metabolic risk factors for chronic disease over 20 years: findings from the 1998–2018 Korea National Health and Nutrition Examination Survey Epidemiol Health 2021 43 e2021028 10.4178/epih.e2021028 33872481
Kim Y, Nho SJ, Woo G, Kim H, Park S, Kim Y, et al. Trends in the prevalence and management of major metabolic risk factors for chronic disease over 20 years: findings from the 1998–2018 Korea National Health and Nutrition Examination Survey. Epidemiol Health. 2021;43:e2021028.33872481 10.4178/epih.e2021028
23. Lee GB Kim Y Park S Kim HC Oh K Obesity, hypertension, diabetes mellitus, and hypercholesterolemia in Korean adults before and during the COVID-19 pandemic: a special report of the 2020 Korea National Health and Nutrition Examination Survey Epidemiol Health 2022 44 e2022041 10.4178/epih.e2022041 35538699
Lee GB, Kim Y, Park S, Kim HC, Oh K. Obesity, hypertension, diabetes mellitus, and hypercholesterolemia in Korean adults before and during the COVID-19 pandemic: a special report of the 2020 Korea National Health and Nutrition Examination Survey. Epidemiol Health. 2022;44:e2022041.35538699 10.4178/epih.e2022041
24. Onuh JO Aliani M Metabolomics profiling in hypertension and blood pressure regulation: a review Clin Hypertens 2020 26 1 23 10.1186/s40885-020-00157-9 33292736
Onuh JO, Aliani M. Metabolomics profiling in hypertension and blood pressure regulation: a review. Clin Hypertens. 2020;26(1):23.33292736 10.1186/s40885-020-00157-9
25. American College of Cardiology/American Heart Association Task Force on Practice Guidelines OEP. Expert Panel Report: Guidelines (2013) for the management of overweight and obesity in adults. Obesity (Silver Spring). 2014;22 Suppl 2:S41–410.
26. Foster GD Wyatt HR Hill JO McGuckin BG Brill C Mohammed BS A randomized trial of a low-carbohydrate diet for obesity N Engl J Med 2003 348 21 2082 2090 10.1056/NEJMoa022207 12761365
Foster GD, Wyatt HR, Hill JO, McGuckin BG, Brill C, Mohammed BS, et al. A randomized trial of a low-carbohydrate diet for obesity. N Engl J Med. 2003;348(21):2082–90.12761365 10.1056/NEJMoa022207
27. Choi JH Cho YJ Kim HJ Ko SH Chon S Kang JH Effect of carbohydrate-restricted diets and intermittent fasting on obesity, type 2 diabetes mellitus, and hypertension management: consensus statement of the Korean Society for the Study of obesity, Korean Diabetes Association, and Korean Society of Hypertension Clin Hypertens 2022 28 1 26 10.1186/s40885-022-00207-4 35642007
Choi JH, Cho YJ, Kim HJ, Ko SH, Chon S, Kang JH, et al. Effect of carbohydrate-restricted diets and intermittent fasting on obesity, type 2 diabetes mellitus, and hypertension management: consensus statement of the Korean Society for the Study of obesity, Korean Diabetes Association, and Korean Society of Hypertension. Clin Hypertens. 2022;28(1):26.35642007 10.1186/s40885-022-00207-4
28. Ge L Sadeghirad B Ball GDC da Costa BR Hitchcock CL Svendrovski A Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials BMJ 2020 369 m696 10.1136/bmj.m696 32238384
Ge L, Sadeghirad B, Ball GDC, da Costa BR, Hitchcock CL, Svendrovski A, et al. Comparison of dietary macronutrient patterns of 14 popular named dietary programmes for weight and cardiovascular risk factor reduction in adults: systematic review and network meta-analysis of randomised trials. BMJ. 2020;369:m696.32238384 10.1136/bmj.m696
29. Rondanelli M Faliva MA Gasparri C Peroni G Spadaccini D Maugeri R Current opinion on dietary advice in order to preserve fat-free mass during a low-calorie diet Nutrition 2020 72 110667 10.1016/j.nut.2019.110667 31962189
Rondanelli M, Faliva MA, Gasparri C, Peroni G, Spadaccini D, Maugeri R, et al. Current opinion on dietary advice in order to preserve fat-free mass during a low-calorie diet. Nutrition. 2020;72:110667.31962189 10.1016/j.nut.2019.110667
30. Bellicha A, van Baak MA, Battista F, Beaulieu K, Blundell JE, Busetto L, et al. Effect of exercise training on weight loss, body composition changes, and weight maintenance in adults with overweight or obesity: An overview of 12 systematic reviews and 149 studies. Obes Rev. 2021;22 Suppl 4(Suppl 4):e13256.
31. Kim KK Haam JH Kim BT Kim EM Park JH Rhee SY Evaluation and Treatment of Obesity and Its Comorbidities: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity J Obes Metab Syndr 2023 32 1 1 24 10.7570/jomes23016 36945077
Kim KK, Haam JH, Kim BT, Kim EM, Park JH, Rhee SY, et al. Evaluation and Treatment of Obesity and Its Comorbidities: 2022 Update of Clinical Practice Guidelines for Obesity by the Korean Society for the Study of Obesity. J Obes Metab Syndr. 2023;32(1):1–24.36945077 10.7570/jomes23016
32. Kim BY Kang SM Kang JH Kang SY Kim KK Kim KB 2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea J Obes Metab Syndr 2021 30 2 81 92 10.7570/jomes21022 34045368
Kim BY, Kang SM, Kang JH, Kang SY, Kim KK, Kim KB, et al. 2020 Korean Society for the Study of Obesity Guidelines for the Management of Obesity in Korea. J Obes Metab Syndr. 2021;30(2):81–92.34045368 10.7570/jomes21022
33. Kim BY Kang SM Kang JH Kim KK Kim B Kim SJ Current Long-Term Pharmacotherapies for the Management of Obesity J Obes Metab Syndr 2020 29 2 99 109 10.7570/jomes20010 32378399
Kim BY, Kang SM, Kang JH, Kim KK, Kim B, Kim SJ, et al. Current Long-Term Pharmacotherapies for the Management of Obesity. J Obes Metab Syndr. 2020;29(2):99–109.32378399 10.7570/jomes20010
34. Garvey WT Mechanick JI Brett EM Garber AJ Hurley DL Jastreboff AM American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity Endocr Pract 2016 22 Suppl 3 1 203 10.4158/EP161365.GL 27219496
Garvey WT, Mechanick JI, Brett EM, Garber AJ, Hurley DL, Jastreboff AM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl 3):1–203.27219496 10.4158/EP161365.GL
35. Bayliss WM Starling EH The mechanism of pancreatic secretion J Physiol 1902 28 5 325 353 10.1113/jphysiol.1902.sp000920 16992627
Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol. 1902;28(5):325–53.16992627 10.1113/jphysiol.1902.sp000920
36. Brown JC Mutt V Pederson RA Further purification of a polypeptide demonstrating enterogastrone activity J Physiol 1970 209 1 57 64 10.1113/jphysiol.1970.sp009155 5499047
Brown JC, Mutt V, Pederson RA. Further purification of a polypeptide demonstrating enterogastrone activity. J Physiol. 1970;209(1):57–64.5499047 10.1113/jphysiol.1970.sp009155
37. Bell GI Sanchez-Pescador R Laybourn PJ Najarian RC Exon duplication and divergence in the human preproglucagon gene Nature 1983 304 5924 368 371 10.1038/304368a0 6877358
Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC. Exon duplication and divergence in the human preproglucagon gene. Nature. 1983;304(5924):368–71.6877358 10.1038/304368a0
38. Nauck MA Heimesaat MM Orskov C Holst JJ Ebert R Creutzfeldt W Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus J Clin Invest 1993 91 1 301 307 10.1172/JCI116186 8423228
Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91(1):301–7.8423228 10.1172/JCI116186
39. Deacon CF Nauck MA Toft-Nielsen M Pridal L Willms B Holst JJ Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 1995 44 9 1126 1131 10.2337/diab.44.9.1126 7657039
Deacon CF, Nauck MA, Toft-Nielsen M, Pridal L, Willms B, Holst JJ. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44(9):1126–31.7657039 10.2337/diab.44.9.1126
40. Sharma D Verma S Vaidya S Kalia K Tiwari V Recent updates on GLP-1 agonists: Current advancements & challenges Biomed Pharmacother 2018 108 952 962 10.1016/j.biopha.2018.08.088 30372907
Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V. Recent updates on GLP-1 agonists: Current advancements & challenges. Biomed Pharmacother. 2018;108:952–62.30372907 10.1016/j.biopha.2018.08.088
41. Meier JJ GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus Nat Rev Endocrinol 2012 8 12 728 742 10.1038/nrendo.2012.140 22945360
Meier JJ. GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2012;8(12):728–42.22945360 10.1038/nrendo.2012.140
42. Buckley ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Rønne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467).
43. Merchenthaler I Lane M Shughrue P Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system J Comp Neurol 1999 403 2 261 280 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5 9886047
Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol. 1999;403(2):261–80.9886047 10.1002/(SICI)1096-9861(19990111)403:2<261::AID-CNE8>3.0.CO;2-5
44. Ban K Noyan-Ashraf MH Hoefer J Bolz SS Drucker DJ Husain M Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways Circulation 2008 117 18 2340 2350 10.1161/CIRCULATIONAHA.107.739938 18427132
Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation. 2008;117(18):2340–50.18427132 10.1161/CIRCULATIONAHA.107.739938
45. Nauck MA Quast DR Wefers J Meier JJ GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art Mol Metab 2021 46 101102 10.1016/j.molmet.2020.101102 33068776
Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Mol Metab. 2021;46: 101102.33068776 10.1016/j.molmet.2020.101102
46. Carabotti M Scirocco A Maselli MA Severi C The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems Ann Gastroenterol 2015 28 2 203 209 25830558
Carabotti M, Scirocco A, Maselli MA, Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28(2):203–9.25830558
47. Salehi M Purnell JQ The Role of Glucagon-Like Peptide-1 in Energy Homeostasis Metab Syndr Relat Disord 2019 17 4 183 191 10.1089/met.2018.0088 30720393
Salehi M, Purnell JQ. The Role of Glucagon-Like Peptide-1 in Energy Homeostasis. Metab Syndr Relat Disord. 2019;17(4):183–91.30720393 10.1089/met.2018.0088
48. Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 9548 1696 1705 10.1016/S0140-6736(06)69705-5 17098089
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–705.17098089 10.1016/S0140-6736(06)69705-5
49. Nauck M Marre M Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits Postgrad Med 2009 121 3 5 15 10.3810/pgm.2009.05.1997 19491535
Nauck M, Marre M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. Postgrad Med. 2009;121(3):5–15.19491535 10.3810/pgm.2009.05.1997
50. Davies MJ Bergenstal R Bode B Kushner RF Lewin A Skjoth TV Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial JAMA 2015 314 7 687 699 10.1001/jama.2015.9676 26284720
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687–99.26284720 10.1001/jama.2015.9676
51. Secher A Jelsing J Baquero AF Hecksher-Sorensen J Cowley MA Dalboge LS The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss J Clin Invest 2014 124 10 4473 4488 10.1172/JCI75276 25202980
Secher A, Jelsing J, Baquero AF, Hecksher-Sorensen J, Cowley MA, Dalboge LS, et al. The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest. 2014;124(10):4473–88.25202980 10.1172/JCI75276
52 Gabery S Salinas CG Paulsen SJ Ahnfelt-Ronne J Alanentalo T Baquero AF Semaglutide lowers body weight in rodents via distributed neural pathways JCI Insight. 2020 5 6 e133429 10.1172/jci.insight.133429 32213703
Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Ronne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429.32213703 10.1172/jci.insight.133429
53. Blundell J Finlayson G Axelsen M Flint A Gibbons C Kvist T Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity Diabetes Obes Metab 2017 19 9 1242 1251 10.1111/dom.12932 28266779
Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017;19(9):1242–51.28266779 10.1111/dom.12932
54. Kadouh H Chedid V Halawi H Burton DD Clark MM Khemani D GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity J Clin Endocrinol Metab 2020 105 5 1552 1563 10.1210/clinem/dgz140 31665455
Kadouh H, Chedid V, Halawi H, Burton DD, Clark MM, Khemani D, et al. GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity. J Clin Endocrinol Metab. 2020;105(5):1552–63.31665455 10.1210/clinem/dgz140
55. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 3. Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2023. Diabetes Care. 2023;46(Suppl 1):S41-S8.
56. Hamman RF Wing RR Edelstein SL Lachin JM Bray GA Delahanty L Effect of weight loss with lifestyle intervention on risk of diabetes Diabetes Care 2006 29 9 2102 2107 10.2337/dc06-0560 16936160
Hamman RF, Wing RR, Edelstein SL, Lachin JM, Bray GA, Delahanty L, et al. Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care. 2006;29(9):2102–7.16936160 10.2337/dc06-0560
57. Lean ME Leslie WS Barnes AC Brosnahan N Thom G McCombie L Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial Lancet 2018 391 10120 541 551 10.1016/S0140-6736(17)33102-1 29221645
Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541–51.29221645 10.1016/S0140-6736(17)33102-1
58. Christensen P Meinert Larsen T Westerterp-Plantenga M Macdonald I Martinez JA Handjiev S Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW) Diabetes Obes Metab 2018 20 12 2840 2851 10.1111/dom.13466 30088336
Christensen P, Meinert Larsen T, Westerterp-Plantenga M, Macdonald I, Martinez JA, Handjiev S, et al. Men and women respond differently to rapid weight loss: Metabolic outcomes of a multi-centre intervention study after a low-energy diet in 2500 overweight, individuals with pre-diabetes (PREVIEW). Diabetes Obes Metab. 2018;20(12):2840–51.30088336 10.1111/dom.13466
59. Taha MB Yahya T Satish P Laird R Agatston AS Cainzos-Achirica M Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management Curr Atheroscler Rep 2022 24 8 643 654 10.1007/s11883-022-01041-7 35624390
Taha MB, Yahya T, Satish P, Laird R, Agatston AS, Cainzos-Achirica M, et al. Glucagon-Like Peptide 1 Receptor Agonists: A Medication for Obesity Management. Curr Atheroscler Rep. 2022;24(8):643–54.35624390 10.1007/s11883-022-01041-7
60. Pi-Sunyer X Astrup A Fujioka K Greenway F Halpern A Krempf M A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management N Engl J Med. 2015 373 1 11 22 10.1056/NEJMoa1411892 26132939
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11–22.26132939 10.1056/NEJMoa1411892
61. le Roux CW Astrup A Fujioka K Greenway F Lau DCW Van Gaal L 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial Lancet 2017 389 10077 1399 1409 10.1016/S0140-6736(17)30069-7 28237263
le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, et al. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389(10077):1399–409.28237263 10.1016/S0140-6736(17)30069-7
62. Wilding JPH Batterham RL Calanna S Davies M Van Gaal LF Lingvay I Once-Weekly Semaglutide in Adults with Overweight or Obesity N Engl J Med 2021 384 11 989 1002 10.1056/NEJMoa2032183 33567185
Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002.33567185 10.1056/NEJMoa2032183
63. Wang W Wei R Huang Z Luo J Pan Q Guo L Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis Diabetes Metab Res Rev 2023 39 7 e3680 10.1002/dmrr.3680 37356073
Wang W, Wei R, Huang Z, Luo J, Pan Q, Guo L. Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis. Diabetes Metab Res Rev. 2023;39(7):e3680.37356073 10.1002/dmrr.3680
64. Yeh TL Tsai MC Tsai WH Tu YK Chien KL Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis PLoS ONE 2023 18 1 e0278685 10.1371/journal.pone.0278685 36696429
Yeh TL, Tsai MC, Tsai WH, Tu YK, Chien KL. Effect of glucagon-like peptide-1 receptor agonists on glycemic control, and weight reduction in adults: A multivariate meta-analysis. PLoS ONE. 2023;18(1):e0278685.36696429 10.1371/journal.pone.0278685
65. Bae JH Han KD Ko SH Yang YS Choi JH Choi KM Diabetes Fact Sheet in Korea 2021 Diabetes Metab J. 2022 46 3 417 426 10.4093/dmj.2022.0106 35656565
Bae JH, Han KD, Ko SH, Yang YS, Choi JH, Choi KM, et al. Diabetes Fact Sheet in Korea 2021. Diabetes Metab J. 2022;46(3):417–26.35656565 10.4093/dmj.2022.0106
66. Asmar A Simonsen L Asmar M Madsbad S Holst JJ Frandsen E Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men American Journal of Physiology-Endocrinology and Metabolism 2015 308 8 E641 E649 10.1152/ajpendo.00429.2014 25670826
Asmar A, Simonsen L, Asmar M, Madsbad S, Holst JJ, Frandsen E, et al. Renal extraction and acute effects of glucagon-like peptide-1 on central and renal hemodynamics in healthy men. American Journal of Physiology-Endocrinology and Metabolism. 2015;308(8):E641–9.25670826 10.1152/ajpendo.00429.2014
67. Pfeffer MA Claggett B Diaz R Dickstein K Gerstein HC Kober LV Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome N Engl J Med 2015 373 23 2247 2257 10.1056/NEJMoa1509225 26630143
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Kober LV, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247–57.26630143 10.1056/NEJMoa1509225
68. Marso SP Bain SC Consoli A Eliaschewitz FG Jodar E Leiter LA Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes N Engl J Med 2016 375 19 1834 1844 10.1056/NEJMoa1607141 27633186
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834–44.27633186 10.1056/NEJMoa1607141
69. Marso SP Daniels GH Brown-Frandsen K Kristensen P Mann JF Nauck MA Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 2016 375 4 311 322 10.1056/NEJMoa1603827 27295427
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311–22.27295427 10.1056/NEJMoa1603827
70. Holman RR Bethel MA Mentz RJ Thompson VP Lokhnygina Y Buse JB Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes N Engl J Med 2017 377 13 1228 1239 10.1056/NEJMoa1612917 28910237
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228–39.28910237 10.1056/NEJMoa1612917
71. Hernandez AF Green JB Janmohamed S D'Agostino RB Sr Granger CB Jones NP Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Lancet 2018 392 10157 1519 1529 10.1016/S0140-6736(18)32261-X 30291013
Hernandez AF, Green JB, Janmohamed S, D’Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.30291013 10.1016/S0140-6736(18)32261-X
72. Gerstein HC Colhoun HM Dagenais GR Diaz R Lakshmanan M Pais P Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial Lancet 2019 394 10193 121 130 10.1016/S0140-6736(19)31149-3 31189511
Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.31189511 10.1016/S0140-6736(19)31149-3
73. Husain M Birkenfeld AL Donsmark M Dungan K Eliaschewitz FG Franco DR Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes N Engl J Med 2019 381 9 841 851 10.1056/NEJMoa1901118 31185157
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841–51.31185157 10.1056/NEJMoa1901118
74. Kosiborod MN Abildstrom SZ Borlaug BA Butler J Rasmussen S Davies M Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity N Engl J Med 2023 389 12 1069 1084 10.1056/NEJMoa2306963 37622681
Kosiborod MN, Abildstrom SZ, Borlaug BA, Butler J, Rasmussen S, Davies M, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023;389(12):1069–84.37622681 10.1056/NEJMoa2306963
75. Lincoff AM Brown-Frandsen K Colhoun HM Deanfield J Emerson SS Esbjerg S Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes N Engl J Med 2023 389 24 2221 2232 10.1056/NEJMoa2307563 37952131
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221–32.37952131 10.1056/NEJMoa2307563
76. Sun F Wu S Guo S Yu K Yang Z Li L Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis Diabetes Res Clin Pract 2015 110 1 26 37 10.1016/j.diabres.2015.07.015 26358202
Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, et al. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015;110(1):26–37.26358202 10.1016/j.diabres.2015.07.015
77. Goud A Zhong J Peters M Brook RD Rajagopalan S GLP-1 agonists and blood pressure: a review of the evidence Curr Hypertens Rep 2016 18 1 11 10.1007/s11906-015-0621-6 26694820
Goud A, Zhong J, Peters M, Brook RD, Rajagopalan S. GLP-1 agonists and blood pressure: a review of the evidence. Curr Hypertens Rep. 2016;18:1–11.26694820 10.1007/s11906-015-0621-6
78. Ribeiro-Silva JC Tavares CA Girardi AC The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms Curr Opin Pharmacol 2023 69 102355 10.1016/j.coph.2023.102355 36857807
Ribeiro-Silva JC, Tavares CA, Girardi AC. The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the potential mechanisms. Curr Opin Pharmacol. 2023;69:102355.36857807 10.1016/j.coph.2023.102355
79. Hu M Cai X Yang W Zhang S Nie L Ji L Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus: a meta-analysis J Am Heart Assoc 2020 9 7 e015323 10.1161/JAHA.119.015323 32223390
Hu M, Cai X, Yang W, Zhang S, Nie L, Ji L. Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus: a meta-analysis. J Am Heart Assoc. 2020;9(7):e015323.32223390 10.1161/JAHA.119.015323
80. Ferdinand KC White WB Calhoun DA Lonn EM Sager PT Brunelle R Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus Hypertension 2014 64 4 731 737 10.1161/HYPERTENSIONAHA.114.03062 24980665
Ferdinand KC, White WB, Calhoun DA, Lonn EM, Sager PT, Brunelle R, et al. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus. Hypertension. 2014;64(4):731–7.24980665 10.1161/HYPERTENSIONAHA.114.03062
81. Fonseca VA DeVries JH Henry RR Donsmark M Thomsen HF Plutzky J Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials J Diabetes Complications 2014 28 3 399 405 10.1016/j.jdiacomp.2014.01.009 24561125
Fonseca VA, DeVries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014;28(3):399–405.24561125 10.1016/j.jdiacomp.2014.01.009
82. Gaspari T Liu H Welungoda I Hu Y Widdop RE Knudsen LB A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/-mouse model Diab Vasc Dis Res 2011 8 2 117 124 10.1177/1479164111404257 21562063
Gaspari T, Liu H, Welungoda I, Hu Y, Widdop RE, Knudsen LB, et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/-mouse model. Diab Vasc Dis Res. 2011;8(2):117–24.21562063 10.1177/1479164111404257
83. Nyström T Gonon AT Sjöholm Å Pernow J Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism Regul Pept 2005 125 1–3 173 177 10.1016/j.regpep.2004.08.024 15582729
Nyström T, Gonon AT, Sjöholm Å, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005;125(1–3):173–7.15582729 10.1016/j.regpep.2004.08.024
84. Fan S-H Xiong Q-F Wang L Zhang L-H Shi Y-W Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway Mol Cell Endocrinol 2020 518 111005 10.1016/j.mce.2020.111005 32877753
Fan S-H, Xiong Q-F, Wang L, Zhang L-H, Shi Y-W. Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1/2/NF-κB signalling pathway. Mol Cell Endocrinol. 2020;518:111005.32877753 10.1016/j.mce.2020.111005
85. Kim M Platt MJ Shibasaki T Quaggin SE Backx PH Seino S GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure Nat Med 2013 19 5 567 575 10.1038/nm.3128 23542788
Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19(5):567–75.23542788 10.1038/nm.3128
86. Moreno C Mistry M Roman RJ Renal effects of glucagon-like peptide in rats Eur J Pharmacol 2002 434 3 163 167 10.1016/S0014-2999(01)01542-4 11779579
Moreno C, Mistry M, Roman RJ. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol. 2002;434(3):163–7.11779579 10.1016/S0014-2999(01)01542-4
87. Gutzwiller J-P Tschopp S Bock A Zehnder CE Huber AR Kreyenbuehl M Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men J Clin Endocrinol Metab 2004 89 6 3055 3061 10.1210/jc.2003-031403 15181098
Gutzwiller J-P, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab. 2004;89(6):3055–61.15181098 10.1210/jc.2003-031403
88. Katsurada K Nakata M Saito T Zhang B Maejima Y Nandi SS Central glucagon-like peptide-1 receptor signaling via brainstem catecholamine neurons counteracts hypertension in spontaneously hypertensive rats Sci Rep 2019 9 1 12986 10.1038/s41598-019-49364-x 31537818
Katsurada K, Nakata M, Saito T, Zhang B, Maejima Y, Nandi SS, et al. Central glucagon-like peptide-1 receptor signaling via brainstem catecholamine neurons counteracts hypertension in spontaneously hypertensive rats. Sci Rep. 2019;9(1):12986.31537818 10.1038/s41598-019-49364-x
89. Pauza AG Thakkar P Tasic T Felippe I Bishop P Greenwood MP GLP1R attenuates sympathetic response to high glucose via carotid body inhibition Circ Res 2022 130 5 694 707 10.1161/CIRCRESAHA.121.319874 35100822
Pauza AG, Thakkar P, Tasic T, Felippe I, Bishop P, Greenwood MP, et al. GLP1R attenuates sympathetic response to high glucose via carotid body inhibition. Circ Res. 2022;130(5):694–707.35100822 10.1161/CIRCRESAHA.121.319874
90. Hattori Y Jojima T Tomizawa A Satoh H Hattori S Kasai K A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells Diabetologia 2010 53 10 2256 2263 10.1007/s00125-010-1831-8 20593161
Hattori Y, Jojima T, Tomizawa A, Satoh H, Hattori S, Kasai K, et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia. 2010;53(10):2256–63.20593161 10.1007/s00125-010-1831-8
91. Ishibashi Y Matsui T Takeuchi M Yamagishi S Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression Biochem Biophys Res Commun 2010 391 3 1405 1408 10.1016/j.bbrc.2009.12.075 20026306
Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Glucagon-like peptide-1 (GLP-1) inhibits advanced glycation end product (AGE)-induced up-regulation of VCAM-1 mRNA levels in endothelial cells by suppressing AGE receptor (RAGE) expression. Biochem Biophys Res Commun. 2010;391(3):1405–8.20026306 10.1016/j.bbrc.2009.12.075
92. Luna-Marco C de Marañon AM Hermo-Argibay A Rodriguez-Hernandez Y Hermenejildo J Fernandez-Reyes M Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes Redox Biol 2023 66 102849 10.1016/j.redox.2023.102849 37591012
Luna-Marco C, de Marañon AM, Hermo-Argibay A, Rodriguez-Hernandez Y, Hermenejildo J, Fernandez-Reyes M, et al. Effects of GLP-1 receptor agonists on mitochondrial function, inflammatory markers and leukocyte-endothelium interactions in type 2 diabetes. Redox Biol. 2023;66:102849.37591012 10.1016/j.redox.2023.102849
93. Rakipovski G, Rolin B, Nøhr J, Klewe I, Frederiksen KS, Augustin R, et al. The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways. JACC: Basic to Translational Science. 2018;3(6):844–57.
94. Anholm C Kumarathurai P Pedersen LR Samkani A Walzem RL Nielsen OW Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial Atherosclerosis 2019 288 60 66 10.1016/j.atherosclerosis.2019.07.007 31326727
Anholm C, Kumarathurai P, Pedersen LR, Samkani A, Walzem RL, Nielsen OW, et al. Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial. Atherosclerosis. 2019;288:60–6.31326727 10.1016/j.atherosclerosis.2019.07.007
95. Roessler J Leistner DM Landmesser U Haghikia A Modulatory role of gut microbiota in cholesterol and glucose metabolism: Potential implications for atherosclerotic cardiovascular disease Atherosclerosis 2022 359 1 12 10.1016/j.atherosclerosis.2022.08.018 36126379
Roessler J, Leistner DM, Landmesser U, Haghikia A. Modulatory role of gut microbiota in cholesterol and glucose metabolism: Potential implications for atherosclerotic cardiovascular disease. Atherosclerosis. 2022;359:1–12.36126379 10.1016/j.atherosclerosis.2022.08.018
96. Holst JJ Deacon CF Vilsboll T Krarup T Madsbad S Glucagon-like peptide-1, glucose homeostasis and diabetes Trends Mol Med 2008 14 4 161 168 10.1016/j.molmed.2008.01.003 18353723
Holst JJ, Deacon CF, Vilsboll T, Krarup T, Madsbad S. Glucagon-like peptide-1, glucose homeostasis and diabetes. Trends Mol Med. 2008;14(4):161–8.18353723 10.1016/j.molmed.2008.01.003
97. Jojima T Uchida K Akimoto K Tomotsune T Yanagi K Iijima T Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice Atherosclerosis 2017 261 44 51 10.1016/j.atherosclerosis.2017.04.001 28445811
Jojima T, Uchida K, Akimoto K, Tomotsune T, Yanagi K, Iijima T, et al. Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice. Atherosclerosis. 2017;261:44–51.28445811 10.1016/j.atherosclerosis.2017.04.001
98. Scalzo RL Rafferty D Schauer I Huebschmann AG Cree-Green M Reusch JEB Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes J Diabetes Complications 2019 33 8 561 566 10.1016/j.jdiacomp.2019.05.002 31182338
Scalzo RL, Rafferty D, Schauer I, Huebschmann AG, Cree-Green M, Reusch JEB, et al. Sitagliptin improves diastolic cardiac function but not cardiorespiratory fitness in adults with type 2 diabetes. J Diabetes Complications. 2019;33(8):561–6.31182338 10.1016/j.jdiacomp.2019.05.002
99. Nomoto H Miyoshi H Furumoto T Oba K Tsutsui H Miyoshi A A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2) PLoS ONE 2015 10 8 e0135854 10.1371/journal.pone.0135854 26284918
Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Miyoshi A, et al. A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2). PLoS ONE. 2015;10(8):e0135854.26284918 10.1371/journal.pone.0135854
100. Li Q Lin Y Wang S Zhang L Guo L GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells Sci Rep 2017 7 1 8008 10.1038/s41598-017-06712-z 28808291
Li Q, Lin Y, Wang S, Zhang L, Guo L. GLP-1 Inhibits High-Glucose-Induced Oxidative Injury of Vascular Endothelial Cells. Sci Rep. 2017;7(1):8008.28808291 10.1038/s41598-017-06712-z
101. Cameron-Vendrig A Reheman A Siraj MA Xu XR Wang Y Lei X Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis Diabetes 2016 65 6 1714 1723 10.2337/db15-1141 26936963
Cameron-Vendrig A, Reheman A, Siraj MA, Xu XR, Wang Y, Lei X, et al. Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis. Diabetes. 2016;65(6):1714–23.26936963 10.2337/db15-1141
102. Kristensen SL Rorth R Jhund PS Docherty KF Sattar N Preiss D Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials Lancet Diabetes Endocrinol 2019 7 10 776 785 10.1016/S2213-8587(19)30249-9 31422062
Kristensen SL, Rorth R, Jhund PS, Docherty KF, Sattar N, Preiss D, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7(10):776–85.31422062 10.1016/S2213-8587(19)30249-9
103. Sattar N Lee MMY Kristensen SL Branch KRH Del Prato S Khurmi NS Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials Lancet Diabetes Endocrinol 2021 9 10 653 662 10.1016/S2213-8587(21)00203-5 34425083
Sattar N, Lee MMY, Kristensen SL, Branch KRH, Del Prato S, Khurmi NS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021;9(10):653–62.34425083 10.1016/S2213-8587(21)00203-5
104. Banerjee M Pal R Mukhopadhyay S Nair K GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials J Clin Endocrinol Metab 2023 108 7 1806 1812 10.1210/clinem/dgad076 36800286
Banerjee M, Pal R, Mukhopadhyay S, Nair K. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2023;108(7):1806–12.36800286 10.1210/clinem/dgad076
105. Gerstein HC Hart R Colhoun HM Diaz R Lakshmanan M Botros FT The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial Lancet Diabetes Endocrinol 2020 8 2 106 114 10.1016/S2213-8587(19)30423-1 31924562
Gerstein HC, Hart R, Colhoun HM, Diaz R, Lakshmanan M, Botros FT, et al. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes Endocrinol. 2020;8(2):106–14.31924562 10.1016/S2213-8587(19)30423-1
106. Strain WD Frenkel O James MA Leiter LA Rasmussen S Rothwell PM Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6 Stroke 2022 53 9 2749 2757 10.1161/STROKEAHA.121.037775 35582947
Strain WD, Frenkel O, James MA, Leiter LA, Rasmussen S, Rothwell PM, et al. Effects of Semaglutide on Stroke Subtypes in Type 2 Diabetes: Post Hoc Analysis of the Randomized SUSTAIN 6 and PIONEER 6. Stroke. 2022;53(9):2749–57.35582947 10.1161/STROKEAHA.121.037775
107. Caruso I Cignarelli A Sorice GP Natalicchio A Perrini S Laviola L Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies Metabolites. 2022 12 2 183 10.3390/metabo12020183 35208256
Caruso I, Cignarelli A, Sorice GP, Natalicchio A, Perrini S, Laviola L, et al. Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies. Metabolites. 2022;12(2):183.35208256 10.3390/metabo12020183
108. Muskiet MHA Tonneijck L Smits MM van Baar MJB Kramer MHH Hoorn EJ GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes Nat Rev Nephrol 2017 13 10 605 628 10.1038/nrneph.2017.123 28869249
Muskiet MHA, Tonneijck L, Smits MM, van Baar MJB, Kramer MHH, Hoorn EJ, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13(10):605–28.28869249 10.1038/nrneph.2017.123
109. Shim SY Jung SJ Kim SU Kim HC Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adults Clin Hypertens 2023 29 1 3 10.1186/s40885-022-00227-0 36641485
Shim SY, Jung SJ, Kim SU, Kim HC. Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adults. Clin Hypertens. 2023;29(1):3.36641485 10.1186/s40885-022-00227-0
110. Eguchi Y Kitajima Y Hyogo H Takahashi H Kojima M Ono M Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J) Hepatol Res 2015 45 3 269 278 10.1111/hepr.12351 24796231
Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M, et al. Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J). Hepatol Res. 2015;45(3):269–78.24796231 10.1111/hepr.12351
111. Trujillo J Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes J Clin Pharm Ther 2020 45 Suppl 1 Suppl 1 43 60 10.1111/jcpt.13225 32910487
Trujillo J. Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes. J Clin Pharm Ther. 2020;45 Suppl 1(Suppl 1):43–60.32910487 10.1111/jcpt.13225
112. Bettge K, Kahle M, Abd El Aziz MS, Meier JJ, Nauck MA. Occurrence of nausea vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials. Diabetes Obes Metab. 2017;19(3):336–47.
113. He L Wang J Ping F Yang N Huang J Li Y Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials JAMA Intern Med 2022 182 5 513 519 10.1001/jamainternmed.2022.0338 35344001
He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases: A Systematic Review and Meta-analysis of Randomized Clinical Trials. JAMA Intern Med. 2022;182(5):513–9.35344001 10.1001/jamainternmed.2022.0338
114. Woronow D Chamberlain C Niak A Avigan M Houstoun M Kortepeter C Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration JAMA Intern Med 2022 182 10 1104 1106 10.1001/jamainternmed.2022.3810 36036939
Woronow D, Chamberlain C, Niak A, Avigan M, Houstoun M, Kortepeter C. Acute Cholecystitis Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists Reported to the US Food and Drug Administration. JAMA Intern Med. 2022;182(10):1104–6.36036939 10.1001/jamainternmed.2022.3810
115. Gier B Matveyenko AV Kirakossian D Dawson D Dry SM Butler PC Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model Diabetes 2012 61 5 1250 1262 10.2337/db11-1109 22266668
Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes. 2012;61(5):1250–62.22266668 10.2337/db11-1109
116. Egan AG Blind E Dunder K de Graeff PA Hummer BT Bourcier T Pancreatic safety of incretin-based drugs–FDA and EMA assessment N Engl J Med 2014 370 9 794 797 10.1056/NEJMp1314078 24571751
Egan AG, Blind E, Dunder K, de Graeff PA, Hummer BT, Bourcier T, et al. Pancreatic safety of incretin-based drugs–FDA and EMA assessment. N Engl J Med. 2014;370(9):794–7.24571751 10.1056/NEJMp1314078
117. Filippatos TD Panagiotopoulou TV Elisaf MS Adverse Effects of GLP-1 Receptor Agonists Rev Diabet Stud 2014 11 3–4 202 230 10.1900/RDS.2014.11.202 26177483
Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud. 2014;11(3–4):202–30.26177483 10.1900/RDS.2014.11.202
118. Bjerre Knudsen L Madsen LW Andersen S Almholt K de Boer AS Drucker DJ Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation Endocrinology 2010 151 4 1473 1486 10.1210/en.2009-1272 20203154
Bjerre Knudsen L, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473–86.20203154 10.1210/en.2009-1272
119. Vangoitsenhoven R Mathieu C Van der Schueren B GLP1 and cancer: friend or foe? Endocr Relat Cancer 2012 19 5 F77 88 10.1530/ERC-12-0111 22691625
Vangoitsenhoven R, Mathieu C, Van der Schueren B. GLP1 and cancer: friend or foe? Endocr Relat Cancer. 2012;19(5):F77-88.22691625 10.1530/ERC-12-0111
120. Pradhan R Patorno E Tesfaye H Schneeweiss S Yin H Franklin J Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study Am J Epidemiol 2022 191 8 1352 1367 10.1093/aje/kwac021 35136902
Pradhan R, Patorno E, Tesfaye H, Schneeweiss S, Yin H, Franklin J, et al. Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: A Multisite Population-Based Cohort Study. Am J Epidemiol. 2022;191(8):1352–67.35136902 10.1093/aje/kwac021
121. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925–66.
122. Cosentino F Grant PJ Aboyans V Bailey CJ Ceriello A Delgado V 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD Eur Heart J 2020 41 2 255 323 10.1093/eurheartj/ehz486 31497854
Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.31497854 10.1093/eurheartj/ehz486
123. Cawley J Biener A Meyerhoefer C Ding Y Zvenyach T Smolarz BG Direct medical costs of obesity in the United States and the most populous states J Manag Care Spec Pharm 2021 27 3 354 366 33470881
Cawley J, Biener A, Meyerhoefer C, Ding Y, Zvenyach T, Smolarz BG, et al. Direct medical costs of obesity in the United States and the most populous states. J Manag Care Spec Pharm. 2021;27(3):354–66.33470881
124. Visscher TL Seidell JC The public health impact of obesity Annu Rev Public Health 2001 22 355 375 10.1146/annurev.publhealth.22.1.355 11274526
Visscher TL, Seidell JC. The public health impact of obesity. Annu Rev Public Health. 2001;22:355–75.11274526 10.1146/annurev.publhealth.22.1.355
125. Gomez Lumbreras A Tan MS Villa-Zapata L Ilham S Earl JC Malone DC Cost-effectiveness analysis of five anti-obesity medications from a US payer's perspective Nutr Metab Cardiovasc Dis 2023 33 6 1268 1276 10.1016/j.numecd.2023.03.012 37088648
Gomez Lumbreras A, Tan MS, Villa-Zapata L, Ilham S, Earl JC, Malone DC. Cost-effectiveness analysis of five anti-obesity medications from a US payer’s perspective. Nutr Metab Cardiovasc Dis. 2023;33(6):1268–76.37088648 10.1016/j.numecd.2023.03.012
126. Hu Y Zheng SL Ye XL Shi JN Zheng XW Pan HS Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting Ann Transl Med 2022 10 3 152 10.21037/atm-22-200 35284548
Hu Y, Zheng SL, Ye XL, Shi JN, Zheng XW, Pan HS, et al. Cost-effectiveness analysis of 4 GLP-1RAs in the treatment of obesity in a US setting. Ann Transl Med. 2022;10(3):152.35284548 10.21037/atm-22-200
127. Kim N Wang J Burudpakdee C Song Y Ramasamy A Xie Y Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States J Manag Care Spec Pharm. 2022 28 7 740 52 35737858
Kim N, Wang J, Burudpakdee C, Song Y, Ramasamy A, Xie Y, et al. Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. J Manag Care Spec Pharm. 2022;28(7):740–52.35737858
128. Lim F Bellows BK Tan SX Aziz Z Woo Baidal JA Kelly AS Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents JAMA Netw Open 2023 6 8 e2329178 10.1001/jamanetworkopen.2023.29178 37651143
Lim F, Bellows BK, Tan SX, Aziz Z, Woo Baidal JA, Kelly AS, et al. Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents. JAMA Netw Open. 2023;6(8):e2329178.37651143 10.1001/jamanetworkopen.2023.29178
129 Saumoy M Gandhi D Buller S Patel S Schneider Y Cote G Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses Gut. 2023 72 12 2250 2259 10.1136/gutjnl-2023-330437 37524445
Saumoy M, Gandhi D, Buller S, Patel S, Schneider Y, Cote G, et al. Cost-effectiveness of endoscopic, surgical and pharmacological obesity therapies: a microsimulation and threshold analyses. Gut. 2023;72(12):2250–9.37524445 10.1136/gutjnl-2023-330437
130. Jannah N Hild J Gallagher C Dietz W Coverage for Obesity Prevention and Treatment Services: Analysis of Medicaid and State Employee Health Insurance Programs Obesity (Silver Spring) 2018 26 12 1834 1840 10.1002/oby.22307 30426721
Jannah N, Hild J, Gallagher C, Dietz W. Coverage for Obesity Prevention and Treatment Services: Analysis of Medicaid and State Employee Health Insurance Programs. Obesity (Silver Spring). 2018;26(12):1834–40.30426721 10.1002/oby.22307
131. Eberly LA Yang L Essien UR Eneanya ND Julien HM Luo J Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US JAMA Health Forum 2021 2 12 e214182 10.1001/jamahealthforum.2021.4182 35977298
Eberly LA, Yang L, Essien UR, Eneanya ND, Julien HM, Luo J, et al. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US. JAMA Health Forum. 2021;2(12):e214182.35977298 10.1001/jamahealthforum.2021.4182
132. Global H, Population Project on Access to Care for Cardiometabolic D. Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis. Lancet Diabetes Endocrinol. 2021;9(12):825–36.
133. Tokarek J Budny E Saar M Stanczak K Wojtanowska E Mlynarska E Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes Biomedicines. 2023 11 10 2611 10.3390/biomedicines11102611 37892985
Tokarek J, Budny E, Saar M, Stanczak K, Wojtanowska E, Mlynarska E, et al. Molecular Processes Involved in the Shared Pathways between Cardiovascular Diseases and Diabetes. Biomedicines. 2023;11(10):2611.37892985 10.3390/biomedicines11102611
